Clinical Trial Update: Anti-VEGF Therapy for Acute Thyroid Eye Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating anti-VEGF therapy for acute thyroid eye disease has completed, potentially informing efficacy and safety signals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Ophthalmopathy

Drugs mentioned

• Anti-VEGF therapy (unspecified agent)

Snippet

Sponsor: Massachusetts Eye and Ear Infirmary | Conditions: Thyroid Eye Disease | Phase 2 | Status: COMPLETED